

SECURITIES AND EXCHANGE COMMISSION

FORM 6-K

Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

Filing Date: **2004-05-18** | Period of Report: **2004-05-18**  
SEC Accession No. **0001131399-04-000067**

([HTML Version](#) on [secdatabase.com](#))

FILER

**GLAXOSMITHKLINE PLC**

CIK: **1131399** | IRS No.: **000000000**  
Type: **6-K** | Act: **34** | File No.: **001-15170** | Film No.: **04815154**  
SIC: **2834** Pharmaceutical preparations

Mailing Address	Business Address
980 GREAT WEST ROAD BRENTFORD MIDDLESEX X0 TW8 9GS	980 GREAT WEST ROAD BRENTFORD MIDDLESEX X0 TW8 9GS 011442080475000

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending May 18, 2004

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

--

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: May 18, 2004

By: Lorraine Day

-----

Lorraine Day  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

Director's Interests

I give below details of a change in the interests in Ordinary Shares of GlaxoSmithKline plc in respect of the undermentioned Director arising from the purchase of Ordinary Shares at a price of (pound)11.70 per Ordinary Share on 12 May 2004 through the Company's ShareReward Plan ("the Plan") which Mr Coombe entered on 5 October 2001:

Mr J D Coombe                      Acquisition of 11 Ordinary Shares under the partnership element of the Plan (personal contribution)

Acquisition of 11 Ordinary Shares under the matching element of the Plan (Company contribution)

Mr Coombe and the Company were advised of this information on 13 May 2004.

S M Bicknell  
Company Secretary

13 May 2004

Issued - Monday 17th May 2004, London - LSE Announcement

GLAXOSMITHKLINE PLC  
ANNOUNCES CHANGES TO THE BOARD'S COMMITTEES

BOARD COMMITTEES

Remuneration Committee

The Board has appointed Sir Robert Wilson to succeed Mr McArthur as Chairman of the Remuneration Committee with immediate effect. Mr McArthur is to retire from the Board at the conclusion of today's Annual General Meeting.

Nominations Committee

The Board has appointed Dr Ronaldo Schmitz a member of the Nominations Committee, with immediate effect.

Corporate Responsibility Committee

The Board has appointed Sir Christopher Hogg to Chair the Corporate Responsibility Committee, on an interim basis, following the retirement of Mr McHenry from the Board at the conclusion of the AGM. The Board has also appointed Sir Ian Prosser a member of the Committee following Dr Barzach's retirement from the conclusion of the AGM.

S M Bicknell  
Company Secretary  
17th May 2004

BOARD COMMITTEE MEMBERSHIP  
WITH EFFECT FROM 17TH MAY 2004.

Board Committee	Committee Chairman	Members
Audit	Dr Ronaldo Schmitz	Sir Peter Job Sir Ian Prosser Sir Robert Wilson
Remuneration	Sir Robert Wilson	Mr H Lawrence Culp Jnr.

Mr Crispin Davis  
Sir Peter Job

-----  
Nominations

Sir Christopher Hogg

Sir Ian Prosser  
Dr Ronaldo Schmitz  
-----

Corporate  
Responsibility

Sir Christopher Hogg  
  
(Interim Chairman)  
-----

Sir Ian Prosser  
Dr Lucy Shapiro  
-----

GSK Enquiries:

UK Media enquiries:

Martin Sutton (020) 8047 5502  
David Mawdsley (020) 8047 5502  
Chris Hunter-Ward (020) 8047 5502

US Media enquiries:

Nancy Pekarek (215) 751 7709  
Mary Anne Rhyne (919) 483 2839  
Patricia Seif (215) 751 7709

European Analyst/Investor enquiries:

Duncan Learmouth (020) 8047 5540  
Anita Kidgell (020) 8047 5542  
Philip Thomson (020) 8047 5543

US Analyst/ Investor enquiries:

Frank Murdolo (215) 751 7002  
Tom Curry (215) 751 5419

#### Directors' Interests

I give below details of changes in directors' interests in the Ordinary Shares of GlaxoSmithKline plc.

The Administrators of the GlaxoSmithKline US Retirement Savings Plan ("the Plan") notified GlaxoSmithKline plc on 17 May 2004, that as a result of movement in the fund on 14 May 2004, the number of Ordinary Share ADRs held by the fund had decreased from 18,870,513 to 18,866,129 at an average price of \$41.95.

The Plan is a discretionary fund of which all employees or former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. Two of the Company's directors, Dr J P Garnier and Dr T Yamada are therefore potentially interested in the shares held in the fund from time to time in the same way as other employees or former employees of GlaxoSmithKline plc and its subsidiaries.

S M Bicknell  
Company Secretary

18 May 2004

Issued - Monday 17th May 2004, London - LSE Announcement

#### GLAXOSMITHKLINE PLC - RESULTS OF AGM

GlaxoSmithKline (GSK) announces that at today's Annual General Meeting all resolutions, including those electing and re-electing Board members, were passed by shareholders.

Commenting on the results Sir Christopher Hogg, Chairman of GlaxoSmithKline said "I'm very pleased that all the resolutions have been passed by such a substantial majority."

#### GLAXOSMITHKLINE ANNUAL GENERAL MEETING POLL RESULTS

The following table shows the votes cast for each resolution:

Resolution	Total votes for*	%
1. Adoption of Financial Statements	3,772,569,153	98.61
2. Approval of the Remuneration Report	3,256,510,243	89.49
3. Election of Mr H L Culp	3,915,556,226	99.46
4. Election of Mr C Davis	3,915,875,382	99.46
5. Election of Sir Robert Wilson	3,916,386,157	99.45

6. Election of Dr T Yamada	3,861,633,390	99.33
7. Re-election of Sir Christopher Hogg	3,876,671,124	98.83
8. Re-appointment of Auditors	3,758,892,246	99.32
9. Remuneration of Auditors	3,918,517,277	99.48
10. Authorise donations to EU Political Organisations & incur EU Political Expenditure	3,843,373,653	97.99
11. Disapplication of pre-emption rights***	3,904,964,468	99.00
12. Authority for the Company to purchase its own shares***	3,882,768,808	99.45

Resolution	Total votes against	%	Total votes cast	Abstentions**
1. Adoption of Financial Statements	53,133,367	1.39	3,825,702,520	126,825,561
2. Approval of the Remuneration Report	382,337,135	10.51	3,638,847,378	314,504,441
3. Election of Mr H L Culp	21,302,704	0.54	3,936,858,930	15,669,151
4. Election of Mr C Davis	21,323,427	0.54	3,937,198,809	15,329,272
5. Election of Sir	21,552,354	0.55	3,937,938,511	14,589,570

6. Election of Dr T Yamada	26,051,285	0.67	3,887,684,675	64,843,406
7. Re-election of Sir Christopher Hogg	45,713,506	1.17	3,922,384,630	30,143,451
8. Re-appointment of Auditors	25,819,263	0.68	3,784,711,509	167,816,572
9. Remuneration of Auditors	20,305,032	0.52	3,938,822,309	13,705,772
10. Authorise donations to EU Political Organisations & incur EU Political Expenditure	78,986,180	2.01	3,922,359,833	30,168,248
11. Disapplication of pre-emption rights***	39,246,915	1.00	3,944,211,383	8,316,698
12. Authority for the Company to purchase its own shares***	21,328,838	0.55	3,904,097,646	48,430,435

## Notes:

\* Includes discretionary votes.

\*\* An abstention is not a vote in law and is not counted in the calculation of the proportion of votes "For" or "Against" a resolution.

\*\*\* Indicates Special Resolutions requiring a 75% majority

The following table provides further relevant information:



	GlaxoSmithKline's Fourth AGM (2004)	GlaxoSmithKline's Third AGM (2003)
----- Issued share capital (excluding Treasury Shares) -----	5,921,564,431	6,001,763,774
Total votes cast and abstentions lodged as a % of GSK's issued share capital (excluding Treasury Shares).	66.75%	63.23%
----- Total shareholder population. -----	230,939	241,420
----- Total number of proxies lodged. -----	17,400	18,560
----- % of shareholders who lodged proxies. -----	7.53%	7.69%
----- Number of shareholders, corporate representatives and proxies who attended the AGM -----	349	532

S M Bicknell  
Company Secretary  
17th May 2004

These results will shortly be available on the Company's website [www.gsk.com](http://www.gsk.com).

Enquiries:

UK Media enquiries:	Martin Sutton	(020) 8047 5502
	David Mawdsley	(020) 8047 5502
	Chris Hunter-Ward	(020) 8047 5502
US Media enquiries:	Nancy Pekarek	(215) 751 7709
	Mary Anne Rhyne	(919) 483 2839
	Patricia Seif	(215) 751 7709
European Analyst/Investor enquiries:	Duncan Learmouth	(020) 8047 5540
	Anita Kidgell	(020) 8047 5542
	Philip Thomson	(020) 8047 5543

US Analyst/ Investor enquiries:

Frank Murdolo

(215) 751 7002

Tom Curry

(215) 751 5419